Showing 141-150 of 3150 results for "".
Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andAtopic Dermatitis Journal Club: AD Guidelines May Represent a ‘Paradigm Shift’ in Care
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/atopic-derm-journal-club-ad-guidelines-may-represent-a-paradigm-shift-in-care/24075/In the first video of this series, Derek Chu, MD and Peter Lio, MD talk about new atopic dermatitis (AD) guidelines from the American Academy of Allergy, Asthma and Immunology Joint Task Force. These guidelines potentially represent a reshaping of the approach to AD care and understanding, accordingThe Importance and Utility of GEP Testing
https://practicaldermatology.com/series/updates-in-skin-cancer/the-importance-and-utility-of-gep-testing/35597/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses gene expression profiling technology and its importance in the diagnosis and prognostication of melanomas.DermWireTV: AAD's Diversity Plan, Galderma Acne Data, Nutrafol Pro-Strength Boosters
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aads-diversity-plan-galderma-acne-data-nutrafol-pro-strength-boosters/19903/Kanya Ferguson, MD, FAAD, Chair of the AAD’s Diversity Committee, speaks about the AAD’s new comprehensive, three-year plan focused on Diversity, Equity, and Inclusion. It was approved with unanimous support by the AAD’s Board of Directors. A new survey conducted by Galderma and retinoid brand AklieGraduating from Dermatology Residency into the COVID-19 Job Market
https://practicaldermatology.com/youngmd-connect/resident-resource-center/graduating-from-dermatology-residency-into-the-covid-19-job-market/23437/Third-year dermatology residents are graduating into an uncertain job market. What does the future hold?Get to Know DataDerm
https://practicaldermatology.com/topics/practice-management/get-to-know-dataderm/22067/Practical Dermatology® gets the inside scoop on the AAD's data registry from Marta Van Beek, MD.Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalWhen and How to Review Staff Compensation & Goals
https://practicaldermatology.com/topics/practice-management/when-and-how-to-review-staff-compensation--goals/21130/Don't skip reviews. Provide feedback and recognize good performance.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisGuselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.